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APPENDIX
SUPPLEMENTARY DATA
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.urology.2017
.06.054.
EDITORIAL COMMENT
With this article the authors highlight an ever important clini-
cal question: Do we achieve any meaningful benefit for the patient
with our treatments? They report the updated long-term follow-
up of a matched-pair analysis on adjuvant radiotherapy (RT) for
pT2pN0 prostate cancer (PCa) with a single positive surgical
margin after radical prostatectomy (RP).1 Adjuvant RT was as-
sociated with less local and biochemical recurrences, but this did
not seem to (significantly) translate into less distant metastases
or improved overall survival.
Long-term follow-up of the patient cohort is of extreme im-
portance in this study, certainly because of the general indolent
disease course of these mainly low-grade pT2 patients. Most studies
on adjuvant RT include more patients higher at risk of recur-
rence and thus need shorter follow-up to show significant results
(inherently due to the higher number of events).2 The notewor-
thy median follow up of 20 years could, however, also be a draw-
back for the generalizability of the results with changes in diagnosis,
techniques, (additional) treatments and follow-up over the years.
The continuously changing management and treatments in PCa
make it hard to assess the real impact of 1 parameter on hard
outcome parameters as overall survival when this is not as-
sessed with a randomized clinical trial design. The limitations noted
by the authors are therefore certainly of relevance when inter-
preting their results. The low number of events (low grade pT2
disease), the number of patients (76vs76, included in the his-
torical cohort) and the number of patients at risk at 20 years follow-
up imply that showing a (metastasis free-)survival benefit in this
study is unlikely.
The main goal of adjuvant RT seems however achieved: re-
duction in the risk of local recurrences from 12%to3%. Of the
patients that did not receive adjuvant RT 14% received salvage
RT. Supplementary Table 1 reveals even an impact of adjuvant
RT also on distant metastasis when considering salvage RT as
a competing risk (hazard ratio 0.12 [95% CI 0.02-0.95], P = .04).
The potency of adjuvant RT in R1 disease is herein confirmed.
We need to await the results of the RADICALS, GETUG17
and RAVES trial, who hopefully could give more insight into
the benefit of adjuvant versus early salvage treatments.3,4
The question remains: what is significant prostate cancer and
(how) do we need to treat it? Data of the PIVOT-trial showed
no significant reduction of RP on PCa mortality or overall sur-
vival compared to observation at 20year follow-up.5 The main
goal of cancer treatment is to cure or to considerably prolong
the life of the patient, this with the best possible quality-of-life.
The ever balancing of efficiency/morbidity, effectiveness and cost-
efficiency. In the future, we will need to better identify those
patients at risk of relapse but also keep in mind to look out if
we can change anything on patient outcome by subjecting them
to these additional therapies.6,7 For now, adjuvant RT for all pT2
R1 PCa tumors certainly seems debatable, as well as the preva-
lence of R1 in organ-confined disease.
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AUTHOR REPLY
We thank Poelaert et al for their editorial and for emphasizing
the importance of ensuring a meaningful benefit with the treat-
ments we provide. Our overarching objective should be to op-
timize our patients’ quantity or quality of life.
As such, we respectfully submit that in men with otherwise
no biochemical evidence of disease after radical prostatectomy
(RP), the main goal of adjuvant radiation (ART) should be to
improve survival, not merely to reduce risk of radiographic local
prostate cancer (PCa) recurrence. Prostatic bed recurrences in
the modern era are almost always asymptomatic and can be sal-
vaged. Moreover, local recurrence is virtually always preceded by
biochemical recurrence in the absence of adjuvant hormone
therapy,1 permitting timely detection. Symptomatic local pro-
gression after RP is exceedingly rare.
Conversely, radiation after RP is associated with the poten-
tial for morbidity, including urinary incontinence, bladder neck
strictures, hospital admissions, secondary procedures, and sec-
ondary malignancies.2 Much like the need to reduce overtreat-
ment of newly diagnosed PCa, the routine administration of ART
to all men with any adverse pathologic feature may also consti-
tute overtreatment and needs to be re-evaluated.
Positive surgical margins, extraprostatic extension, and seminal
vesicle invasion are adverse pathologic features after RP that have
classically led to the consideration of ART and were pooled to-
gether in the randomized trials.3-5 Our data draw into question
the use of ART based on a single positive surgical margin as the
only adverse risk factor. In addition to mirroring several find-
ings in the randomized trials, our findings are also consistent with
the paper by Abdollah et al6 that was quoted by Poelaert et al.
They report no benefit with ART in a cohort of men who had
either a positive surgical margin or ≥pT3 disease, unless they also
had 2 or more of the following risk factors: Gleason ≥8, ≥pT3,
or positive lymph nodes.
With 20 years of follow-up in our cohort with pT2R1N0 PCa,
the vast majority of deaths were related to non-PCa causes. Of
note, we did not find an associated metastasis-free survival benefit
in our main analysis or in our sensitivity analysis that consid-
ered salvage radiation as a competing event (see Table 2 and
Supplementary Table S1).
Although the low number of “events” can be criticized, on the
other hand, very few men died of PCa in this population (4 men
who received ART and 3 men who did not receive ART), and
the 20-year risk of distant metastasis for men in the no-ART group
was only 6.7%. Even if we hypothetically demonstrated a 30%
relative risk reduction in distant metastasis, which was only seen
in 1 ART trial,5 this would correspond to a 2.0% absolute risk
reduction in risk of distant metastasis and a number needed to
treat of approximately 50 to prevent metastasis in 1 patient. The
number needed to treat would be even higher to prevent a cancer-
specific death. We must then ask ourselves, even if our study is
underpowered, would this degree of overtreatment be accept-
able in light of the alternative approach of prostate-specific antigen
monitoring and early salvage radiation?
We agree that the clinical trials comparing adjuvant with early
salvage radiation will inform this debate. Until then, we urge cli-
nicians to use a risk-adapted approach, and we caution against
over-reliance on intermediate outcomes in the setting of a disease
with a long natural history and the opportunity for death from
competing causes.
Bimal Bhindi, M.D., C.M., M.Sc., and
R. Jeffrey Karnes, M.D., Department of Urology,
Mayo Clinic, Rochester, MN
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